News
All NewsBlogs
Media
All VideosCase-Based Roundtable SeriesEichenbaum AcornsExpert InterviewsEyeviewsInsightsMedical World NewsPodcastsRapid ReadoutsThe Retina TL;DRViewpoints
Conference
Conference CoverageConference Listing
Publications
Modern Retina Digital EditionSupplements And Featured Publications
More
Resources
Between the LinesCME/CEEYLEA 8mg for nAMD and DME TreatmentSponsored Resources
Partners

Subscribe

  • News
  • Media
  • Conference
  • Publications
  • Resources
  • Partners
  • Subscribe
  • AMD
    • Wet AMD
  • Biosimilar
  • Diabetic Macular Edema
    • Diabetic Eye Awareness
  • Diabetic Retinopathy
  • Geographic Atrophy
  • Imaging
  • Inherited Retinal Diseases
  • Ophthalmology
    • Europe
  • RVO
  • Retina Technology
  • Retinal Surgery
  • Uveitis
Spotlight -
Geographic Atrophy
Advertisement

Sally S. Ong, MD

Advertisement

assistant professor of ophthalmology at the Atrium Health Wake Forest Baptist School of Medicine

Articles by Sally S. Ong, MD

Q&A: Sally S. Ong, MD on the neighborhood-level characteristics associated with delay in surgery and loss to follow-up

BySally S. Ong, MD,Sydney M Crago,Martin David Harp
August 21st 2025

Research reveals how neighborhood social factors impact patients with tractional retinal detachments, highlighting the need for improved access to care and support.

Advertisement

Latest Updated Articles

  • Q&A: Sally S. Ong, MD on the neighborhood-level characteristics associated with delay in surgery and loss to follow-up
    Q&A: Sally S. Ong, MD on the neighborhood-level characteristics associated with delay in surgery and loss to follow-up

    August 21st 2025



Advertisement
Advertisement

Trending on Modern Retina

1

Johnson & Johnson’s TECNIS PureSee EDOF IOL cleared for US market

2

NovaBridge, Visara report positive phase 2a results for dual VEGF-A/ANG-2 inhibitor VIS-101

3

Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO

4

Ocugen completes enrollment in liMeliGhT phase 3 trial of OCU400 for retinitis pigmentosa

5

FDA clears phase I/II trial of SVT-001 cell therapy for familial drusen–associated vision loss

  • About
  • Advertise
  • Editorial
  • Contact Us
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us